Whitehawk Therapeutics (NasdaqCM:AADI) FY Conference Transcript

Summary of Whitehawk Therapeutics FY Conference Call Company Overview - Company: Whitehawk Therapeutics (NasdaqCM:AADI) - Focus: Development of next-generation antibody-drug conjugates (ADCs) targeting various cancer indications [2][3] Key Points Product Pipeline - Whitehawk has advanced two ADC assets into clinical trials: - HWK-007: Targets PTK7, a broadly expressed tumor target [2][15] - HWK-016: Targets MUC16, highly expressed in gynecological cancers [2][15] - A third asset, SEZ6, is expected to enter Phase 1 trials in Q3 2026 [14][16] Differentiation and Technology - Whitehawk's ADCs are based on a novel topoisomerase I inhibitor and advanced linker payload technology, aiming for improved therapeutic index [4][12] - The company emphasizes the importance of bioconjugation techniques that enhance stability and reduce toxicity compared to traditional methods [10][11] - Whitehawk's platform reportedly offers 5-25 times more stability in circulation, contributing to a 3-10x improvement in potency and a 2-3x higher safety margin in non-primate studies [13] Clinical Development and Safety - The company is focused on achieving best-in-class efficacy benchmarks, with target overall response rates (ORR) of 35%-40% for non-small cell cancer and 50% for gynecological cancers [40] - Safety concerns include hematological toxicities and interstitial lung disease (ILD), with a focus on minimizing these risks through engineering [46][45] Market Potential and Expansion - HWK-007 has potential applications in multiple cancer types, including breast, gastrointestinal, prostate, and head and neck cancers [15] - HWK-016 is positioned as a best-in-class treatment for ovarian and gynecological cancers, with potential expansion into less targeted tumors like mesothelioma and pancreatic cancer [16] - SEZ6 targets neuroendocrine tumors and is expected to be competitive in a crowded market [60] Financial Position and Strategy - Whitehawk ended Q3 2025 with over $160 million in cash, providing a runway into 2028 [5] - The company operates with a capital-efficient model, burning approximately $15 million-$17 million per quarter [63] - Strategic prioritization of programs will depend on clinical data outcomes, with a focus on maximizing the value of each asset [64] Underappreciated Aspects - The company has three clinical programs running in parallel, which is seen as a significant opportunity for value inflection compared to peers with fewer programs [65] Additional Insights - Whitehawk's management team has extensive experience in ADC development, which is critical for operational success [5] - The company aims to leverage clinical validation from previous ADC generations to target high-potential cancer indications with unmet needs [3]